Out-of-pocket spending continues to increase, particularly in cancer care. High out-of-pocket expenditures are associated with increased psychosocial distress, lower adherence, and higher mortality. In order to improve cancer-related outcomes, we must come up with interventions directed at reducing cancer-related financial toxicity. In this article, we highlight the most promising interventions.

The cost of health care in the United States has risen significantly over the last 15 years [1]. Out-of-pocket (OOP) spending has increased simultaneously, particularly in cancer care. OOP costs can have a toxic effect on patients and their families, leading to psychosocial distress, decreased adherence to treatment plans, and increased mortality [2-4].

According to a recent study evaluating trends in oncology-related spending, cancer care expenditures increased by 2.9% per year between 1998 and 2012, after adjusting for inflation [5]. Overall OOP expenditures increased from $5.7 billion to $6.3 billion among non-veteran, non-institutionalized patients. So although the share of expenditures that were OOP declined from 6% to 4.7% during this period, absolute per capita OOP expenditures likely increased or stayed the same [5]. A large proportion of this spending is devoted to medications: in 2013, Americans spent an average of $858 per capita on prescription drugs. This exceeded per capita spending in 19 other industrialized nations [6].

The Affordable Care Act (ACA) has tried to address the burden caused by high OOP costs by creating OOP maximums. In 2016, the annual OOP maximum was $6,850 for an individual [7]. But even this amount, which is roughly equivalent to 22% of the median annual personal income in the United States [8], can be harmful.

In one recent prospective study of 18,166 Medicare beneficiaries, patients who had supplemental, employer-sponsored insurance and a new diagnosis of cancer spent $5,492 per year on their medical care, equivalent to 12.6% of their income. Patients without supplemental insurance on average spent nearly 1.5 times more, at $8,115 per year. This was equivalent to 23.7% of their household income [9]. Patients with a new diagnosis of cancer had 1.86 increased odds of having OOP expenditures in the highest decile, compared to patients without a new diagnosis of cancer [9].

Roughly 30% of cancer survivors nationwide report financial problems associated with their care, at least in part due to these high OOP expenditures [10]. High costs can have a significant impact on the lives of patients and their families. In one national, prospective observational cohort study, patients with lung and colon cancer were surveyed to evaluate the interactions between financial burden, quality of life, and quality of care [11]. Almost half of patients reported having trouble living on their household income. Patients with the highest financial burden tended to be younger and to have a lower household income and poorer quality of life. This study and others have shown that financial burden is associated with increased odds of depressed mood and increased likelihood of worrying about cancer recurrence. Time off work associated with cancer care also correlates with increased indirect financial losses, decreased productivity [12], and reduced savings [13].

Financial toxicity affects not only quality of life, but also length of life. In 2016, Ramsey and colleagues showed that patients with cancer who filed for bankruptcy had a 1.8 higher risk of mortality [2], suggesting a relationship between extreme financial distress and lower survival. Several studies have explored the factors that lead to this excess mortality [14, 15]. One major effect of high OOP costs is decreased adherence [16-19]. In 2014, Dusetzina and colleagues evaluated 1,541 patients with new diagnoses of chronic myeloid leukemia who initiated imatinib therapy between 2002 and 2011 and had insurance at the time of diagnosis [16]. Monthly copayments for the drug ranged from $0 to $4,792 throughout the study period. Patients’ mean health care-related expenditures nearly doubled from 2002 to 2011, and higher copayments were associated with higher rates of therapy discontinuation (adjusted risk ratio 1.70): among patients with higher copayments, 17% discontinued therapy.

Neugut and colleagues found similar results among women with early-stage breast cancer [17]. In their retro-
spective cohort study, adherence was evaluated among women aged over 50 years who were on aromatase inhibitors over a 2-year period. A quarter of patients who had Medicare were found to have a prescription supply gap of more than 45 days without subsequent refills. Another 9% of patients were found to have a medication possession ratio of less than 80%. Higher copays were associated with lower adherence, especially in women aged over 65 years. Non-adherence, in turn, has been shown to be associated with increased mortality in women with breast cancer [14, 15].

Interventions

Over the past few years, several policies have been proposed at the local and federal levels to reduce the financial burdens associated with cancer care. The Affordable Care Act (ACA) implemented several provisions that were aimed at reducing out-of-pocket (OOP) costs. It expanded Medicaid eligibility in 33 states and the District of Columbia [20], closed the Medicare Part D donut hole, and set a limit to OOP spending for patients with private insurance plans, as aforementioned. There is evidence that these policies have increased access and reduced financial burden for many patients [21, 22]. One large retrospective cohort study found that in states that implemented Medicaid expansion, there was a 17% increase in prescriptions and a 36% increase in prescription drug reimbursements to pharmacies [22]. Several other interventions have been proposed to help reduce cancer-related financial toxicity. Here, we offer a brief overview of these interventions.

Low-Income Subsidies

Medicare beneficiaries without supplemental insurance face high OOP costs for oral chemotherapy [9]. Most patients pay thousands of dollars in the first few months of therapy, and then meet the threshold for catastrophic coverage. Medicare offers low-income subsidies (LIS) to Medicare beneficiaries whose incomes are less than 150% of the federal poverty level and have modest assets. Patients who receive these subsidies have no or almost no OOP expenses. Olszewski and colleagues evaluated the association between LIS and use of novel and typically more expensive oral immunomodulatory drugs for multiple myeloma [23]. They found that median OOP costs for the first year of therapy were $6 for LIS recipients, compared to $5,623 for patients who did not qualify for LIS. Patients who received LIS had a 32% higher probability of receiving novel oral immunomodulatory drugs and a 46% lower risk of delays between refills. Although overall survival and cumulative Medicare costs were roughly the same, patients who received novel oral immunomodulatory drugs had fewer emergency room visits and hospitalizations, compared to patients who received an older drug, bortezomib. Although quality of life was not assessed, it is likely that the reduced time spent in hospitals had a positive effect.

Rebates

Many pharmaceutical companies offer rebates for their most expensive drugs. These companies negotiate with health plans or pharmacy benefit managers to ensure inclusion on preferred medication lists, in exchange for lower charges. Health plans often determine patients’ copays and coinsurance percentages before accounting for these rebates. Patients’ OOP expenditures may therefore end up being the same or only slightly lower than if there was no rebate at all. A recent analysis of pharmacy rebates noted that while health plans and pharmacy benefit managers profit from them, patients rarely do [24]. Dusetzina and colleagues have proposed that insurance plans calculate patients’ OOP costs based on net price of the drug after rebates, rather than based on the drug’s list price [24]. The Centers for Medicare & Medicaid Services (CMS) could publicize the plans that offer rebates for certain commonly-used medications. This would likely lead to an improvement in value-based prescription habits.

Patient Assistance Programs

Pharmaceutical companies and charitable foundations have developed programs that help patients afford the high costs of copays, coinsurances, and deductibles [25]. Pharmaceutical patient assistance programs (PAPs) assist only with OOP medication costs. According to PhRMA, the pharmaceutical industry’s lobbying arm, PAPs have helped over 10 million patients pay for their medications [26]. These programs have evidently increased access to expensive medications; however, some argue that they are harmful to the financial well-being of our health care system [25]. First, they may remove the disincentive to use very expensive drugs, thus leading to higher drug prices overall [27, 28]. Second, patients and physicians may opt for drugs that have PAPs available, even if they provide only minimal clinical benefit compared to other drugs. Third, PAP applications involve a significant amount of paperwork. This can act as a barrier to patients with low health literacy and little social support, thus further increasing health disparities. For PAPs to be more effective and accessible, these programs should target patients with the highest financial needs and provide assistance for more than just medication-related costs, such as copays for clinic visits or administration of intravenous anticancer drugs.

Hospital-Based Financial Assistance

Many large cancer centers offer financial assistance to patients who cannot afford their OOP costs. Hospitals often do not publicize the details of their financial assistance programs, but most of them do provide some assistance when needed. Safety net hospitals may forgive patient debt. Large private hospitals may, in contrast, provide payment plans to make hospital bills more manageable. These systems can benefit individual patients who know about them and are
able to sort through the required paperwork. But health systems—especially the largest ones—can and should do more. For example, they should make their prices transparent, so that patients can prepare their budgets ahead of time [29]. Price transparency would also give patients the opportunity to think about their goals of care more carefully and to take the time to look for and apply for PAPs offered by pharmaceutical manufacturers and charitable organizations.

**Drug Price Negotiation**

When the Food and Drug Administration (FDA) approves new drugs, it awards monopoly rights and allows for the establishment of patents. As a result of this market exclusivity, drug manufacturers can set high prices for their drugs [6]. Drug prices do decline once patents expire and generic drugs can be manufactured, but pharmaceutical companies have found numerous strategies for delaying the expiration of their patents. One solution to this problem would be for the government to negotiate initial drug prices with pharmaceutical companies. For example, Medicare already negotiates the costs of many goods and services; Congress should allow Medicare to negotiate drug prices as well [6, 30].

Negotiations could include evidence supporting the effectiveness of the drug compared to other treatment strategies. Similar to the Veterans Health Administration, Medicare could create a drug formulary containing the most effective and least financially burdensome medications. Private insurance markets often follow Medicare’s lead, so patients with private insurance would eventually benefit from this strategy as well. Price negotiation has been successfully implemented in many Northern European countries, as well as in low- and middle-income countries, most notably with antiretroviral drugs used to treat HIV [31].

**Outcome-Based Pricing**

Many newer drugs are expensive even though they have similar or lower efficacy compared to already existing therapies [32]. However, the costs of treatment strategies should be tailored to the evidence supporting them. Chernew and colleagues have proposed a value-based insurance design (VBID) in which insurance plans could encourage the implementation of high-value, cost-effective treatment strategies [33-35]. Alternatively, drug companies could decide how much to charge based on individual patient outcomes. Novartis has followed this strategy with its newly-approved treatment for acute lymphoblastic leukemia, CAR-T. The company has stated that it will only receive reimbursements for its new treatment if patients respond within 1 month of initiation [36]. However, some argue that the 1-month threshold set by Novartis is a relatively low bar for success since the vast majority of patients experience disease response at 1 month. A more substantial outcome by which to measure success might be 12-month recurrence rates [37].

**Alternative Payment Models**

The ACA mandates the use of bundled payment policies for the management of a number of disease processes, such as myocardial infarction, gastrointestinal hemorrhage, diabetes, and end-stage renal disease. So far, cancer care in the United States has not experienced a similar payment reform. A recent study compared a bundled payment pay-for-performance program to a more traditional fee-for-service (FFS) program among breast cancer patients in Taiwan [38]. Adherence to quality indicators was 35% among 4,215 patients in the bundled payment group, compared to 28% among 12,506 patients in the FFS group (P < .001). Five-year survival was significantly higher and costs were significantly lower among patients in the bundled payment group. Based on this and other evidence, CMS is developing the Oncology Care Model, which establishes bundled payment systems for cancer care. The aim of the Oncology Care Model is to improve quality of care, coordination of specialty care, and patient satisfaction, while simultaneously decreasing costs [39].

**Increasing Physician Awareness**

The policy interventions proposed above may take years to be implemented. It may take even longer for the oncology patient population to benefit from them. In the meantime, oncologists and cancer centers should work with patients to lower their OOP expenditures [40]. One recent study found that while about half of cancer patients wanted to discuss finances with their oncologists, only about one-fifth broached this topic during their appointments [41]. Those who discussed costs were 2.6 times more likely to report medication nonadherence. The vast majority of Medicare beneficiaries have expressed the desire for benefits to increase coverage of cancer care, prescription drugs, primary care, home care, palliative care, and nursing home stays [42]. Many physicians do not bring up the topic of costs or benefits with their patients, for a variety of reasons, including lack of knowledge and lack of training [6].

Oncologists should do more to address financial toxicity among their individual patients. First, they should have more frequent goals-of-care discussions with their patients, allowing patients’ care to remain in line with their preferences. Second, they should ask patients early and often whether they are having trouble affording their cancer care. As a result, patients may become familiar with financial assistance programs before their financial burden becomes too high. Third, oncologists should be aware of their patients’ medication-related OOP costs and try to prescribe the highest-value treatment regimens.

**Conclusion**

The association between financial burden and poor outcomes has become increasingly apparent, especially in oncology. Cancer-related financial toxicity affects health-
related quality of life, cancer prevention, adherence to treatment, and mortality; therefore, if our goal moving forward is to improve cancer-related outcomes, we must come up with policy efforts directed at reducing the financial burden associated with necessary life-saving treatments. NCMJ

Caroline Sloan, MD internal medicine resident, Duke University School of Medicine, Durham, North Carolina.

S. Yousuf Zafar, MD, MHS associate professor of medicine, Duke Cancer Institute; affiliate, Duke-Margolis Center for Health Policy, Duke University, Durham, North Carolina.

Acknowledgments
Potential conflicts of interest. S.Y.Z. serves as a consultant for AIM Specialty Health, Genentech, and CG IRB. His spouse is employed by and has stocks in Novartis. C.S. has no relevant conflicts of interest.

References
1. Kaiser Family Foundation. Health care costs: a primer. Kaiser Family Foundation website. https://www.kff.org/health-costs/issue-brief/health-care-costs-a-primer/. Accessed November 4, 2017.
2. Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34(9):980-986.
3. Wollins DS, Zafar SY. A touchy subject: can physicians improve value by discussing costs and clinical benefits with patients? Oncologist. 2016;21(10):1157-1160.
4. Ubel PA, Abernethy AP, Zafar SY. Full disclosure—out-of-pocket costs as side effects. N Engl J Med. 2013;369(16):1484-1486.
5. Lee JA, Roehrig CS, Butto ED. Cancer care cost trends in the United States: 1998 to 2012. Cancer. 2016;122(7):1078-1084.
6. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858-871.
7. HealthCare.gov. Out-of-pocket maximum/limit. HealthCare.gov website. https://www.healthcare.gov/glossary/out-of-pocket-maximum-limit/. Accessed November 4, 2017.
8. U.S. Bureau of the Census, Real Median Personal Income in the United States [MEPAINUSA672N]. St. Louis, MO: FRED. https://fred.stlouisfed.org/series/MEPAINUSA672N. Accessed December 22, 2017.
9. Narang AK, Nicholas LH. Out-of-pocket spending and financial burden among Medicare beneficiaries with cancer. JAMA Oncol. 2017;3(6):775-782.
10. Kale HP, Carroll NV. Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer. 2016;122(8):283-289.
11. Zafar SY, McNeil RB, Thomas CM, Lathan CS, Ayanian JZ, Provenza D. Population-based assessment of cancer survivors’ financial burden and quality of life: a prospective cohort study. J Oncol Pract. 2017;13(2):145-151.
12. Guy GP Jr, Yabroff KR, Ekwueme DU, Rim SH, Li R, Richardson LC. Economic burden of chronic conditions among survivors of cancer in the United States. J Clin Oncol. 2017;35(18):2053-2061.
13. Landwehr MS, Watson SE, Macpherson CF, Novak KA, Johnson RH. The cost of cancer: a retrospective analysis of the financial impact of cancer on young adults. Cancer Med. 2016;5(5):863-870.
14. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529-537.
15. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008;99(1):1763-1768.
16. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306-311.
17. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in the women with early-stage breast cancer. J Clin Oncol. 2011;29(18):2534-2542.
18. Kaul S, Avila JC, Mehta HB, Rodriguez AM, Kuo YF, Kirchhoff AC. Cost-related medication nonadherence among adolescent and young adult cancer survivors. Cancer. 2017;123(14):2726-2734.
19. Farias AJ, Du XL. Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among Medicare patients with breast cancer. J Clin Oncol. 2017;35(18):86-95.
20. The Henry J Kaiser Family Foundation. Status of state action on the Medicaid expansion decision. Kaiser Family Foundation website. https://www.kff.org/health-reform/state-indicator/state-activity-around-expanding-medicaid-under-the-affordable-care-act/. Accessed December 22, 2017.
21. Dixon MS, Cole AL, Dusetzina SB. Out-of-pocket spending under the Affordable Care Act for patients with cancer. Cancer J. 2017;23(3):175-180.
22. Mahendra Ratnam N, Dusetzina SB, Farley JF. Prescription drug utilization and reimbursement increased following state Medicaid expansion in 2014. J Manag Care Spec Pharm. 2017;23(3):355-363.
23. Olaszewski AJ, Dusetzina SB, Eaton CB, Davidoff AJ, Trivedi AN. Subsidies for oral chemotherapy and use of immunomodulatory drugs among Medicare beneficiaries with myeloma. J Clin Oncol. 2017;36(29):3306-3314.
24. Dusetzina SB, Conti RM, Yu NL, Bach PB. Association of prescription drug price rebates in Medicare Part D with patient out-of-pocket and federal spending. JAMA Intern Med. 2017;177(8):1185.
25. Zafar SY, Peppercorn JM. Patient financial assistance programs: a path to affordability or a barrier to accessible cancer care? J Clin Oncol. 2016;35(19):2131-2136.
26. Pharmaceutical Research and Manufacturers of America. Access to medicines: patient assistance. PhRMA website. http://www.phrma.org/access/coverage/patient-assistance. Accessed November 4, 2017.
27. Dafny LS, Ody CJ, Schmitt MA. Undermining Value-Based Purchasing - Lessons from the Pharmaceutical Industry. N Engl J Med. 2016;375(21):2013-2015.
28. Ubel PA, Bach PB. Copay Assistance for expensive drugs: a helping hand that raises costs. Ann Intern Med. 2016;165(12):878-879.
29. Henrikson NB, Shankaran V. Improving Price Transparency in Cancer Care. J Oncol Pract. 2016;12(11):44-47.
30. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2016;17(10):933-980.
31.Juneja S, Gupta A, Moon S, Resch S. Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP). PLoS One. 2017;12(5):e0177770.
32. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium—the just price. J Clin Oncol. 2013;31(28):3600-3604.
33. Chernow ME, Rosen A, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26(2):w195-w203.
34. Fendrick AM, Chernow ME. Value-based insurance design: a “clinically sensitive, fiscally responsible” approach to mitigate the adverse clinical effects of high-deductible consumer-directed health plans. J Gen Intern Med. 2007;22(6):890-891.
35. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139-162.
36. Mukherjee S. Is $475,000 too high a price for Novartis’s “historic” cancer gene therapy? Fortune.com. http://fortune.com/2017/08/31/novartis-kymriah-car-t-cms-price/. Published August 31, 2017. Accessed November 4, 2017.
37. Bach PB, Giralt SA, Saltz LB. FDA approval of Tisagenlecleucel: promise and complexities of a $475,000 cancer drug. JAMA. 2017;318(19):1861-1862.
38. Wang CJ, Cheng SH, Wu JY, et al. Association of a bundled-payment program with cost and outcomes in full-cycle breast cancer care. JAMA Oncol. 2017;3(3):327-334.
39. Center for Medicare and Medicaid Services. Oncology care model. CMS website. https://innovation.cms.gov/initiatives/oncology-care-model/. Accessed November 4, 2017.
40. Zafar SY. Financial toxicity of cancer care: it’s time to intervene. J Natl Cancer Inst. 2016;108(5).
41. Bestvina CM, Zullig LL, Rushing C, et al. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract. 2014;10(3):162-167.
42. Taylor DH Jr, Danis M, Zafar SY, et al. There is a mismatch between the Medicare benefit package and the preferences of patients with cancer and their caregivers. J Clin Oncol. 2014;32(28):3163-3168.